Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions

Pharmacotherapy
Julie C AlfordKavita V Nair

Abstract

To describe the prevalence of prescribing against-label statin-fibrate combination therapy. Retrospective cohort study. Medstat MarketScan Commercial Claims and Encounter database. Adults (aged 18-89 yrs) who were prescribed statin-fibrate combination therapy between January 1, 2003, and June 30, 2009, had pharmacy claims demonstrating two or more concurrently filled prescriptions for a statin and a fibrate, and had continuous insurance enrollment for at least 12 months. Claims data were used to identify patients with dyslipidemia based on International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes. National Drug Codes were used to describe concurrent statin-fibrate combination therapy. The primary outcome was recent use of against-label statin-fibrate combination therapy, defined as use during the last 18 months (January 1, 2008-June 30, 2009) of the study period. Patients were stratified according to statin and dosage to identify against-label combination use (e.g., simvastatin > 10 mg/day with gemfibrozil). Within the recent-use period, 131,394 patients were prescribed concurrent statin-fibrate combination therapy; of these patients, 13,420 (10.2%) had against-label therapy. Simvastatin-ge...Continue Reading

References

Jul 1, 1992·The American Journal of Cardiology·C J GlueckJ Lang
Jul 1, 1991·Neurology·S F LondonS P Ringel
Feb 1, 1990·Annals of Internal Medicine·G E Marais, K K Larson
Apr 1, 1990·Postgraduate Medical Journal·A D Kogan, S Orenstein
Mar 1, 1989·Arthritis and Rheumatism·J A GoldmanR J Johnson
Dec 1, 1995·Journal of Clinical Gastroenterology·N U Abdul-Ghaffar, M R el-Sonbaty
Sep 8, 2000·Clinical Pharmacology and Therapeutics·J T BackmanP J Neuvonen
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
May 24, 2001·Clinical Pharmacology and Therapeutics·C KyrklundP J Neuvonen
Jan 25, 2002·Current Controlled Trials in Cardiovascular Medicine·Curt D Furberg, Bertram Pitt
Feb 19, 2002·The Annals of Pharmacotherapy·Mohamed A Omar, James P Wilson
May 23, 2002·The Journal of Pharmacology and Experimental Therapeutics·Thomayant PrueksaritanontThomas A Baillie
Aug 21, 2002·Circulation·Richard C PasternakUNKNOWN National Heart, Lung and Blood Institute
Oct 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Thomayant PrueksaritanontJiunn H Lin
Nov 16, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jun-Sheng WangPertti J Neuvonen
Jul 23, 2004·Pharmacoepidemiology and Drug Safety·Jennie T ChangLanh Green
Sep 11, 2004·Journal of the American College of Cardiology·Scott M GrundyUNKNOWN Coordinating Committee of the National Cholesterol Education Program
Dec 2, 2004·JAMA : the Journal of the American Medical Association·David J GrahamRichard Platt
Dec 28, 2004·The American Journal of Cardiology·Peter H Jones, Michael H Davidson
Feb 1, 2005·Journal of Clinical Epidemiology·Susan E AndradeK Arnold Chan
May 3, 2005·Journal of Clinical Epidemiology·Sebastian Schneeweiss, Jerry Avorn
Sep 13, 2005·Clinical Pharmacology and Therapeutics·Richard H Ho, Richard B Kim
Jan 13, 2006·The Journal of Clinical Hypertension·Terry A Jacobson, Franklin H Zimmerman
Apr 4, 2006·The American Journal of Cardiology·Mark J CzirakyMichael H Davidson
Dec 21, 2006·Clinical Pharmacology and Therapeutics·Pertti J NeuvonenJanne T Backman
Mar 21, 2007·The American Journal of Cardiology·Michael H DavidsonTerry A Jacobson
Nov 12, 2010·Lancet·UNKNOWN Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative GroupRory Collins

❮ Previous
Next ❯

Citations

Mar 5, 2016·Current Atherosclerosis Reports·Barbara S WigginsPamela B Morris
Oct 29, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Rhianna M TuchschererJoseph J Saseen
Nov 1, 2016·The Annals of Pharmacotherapy·Donald G LamprechtSheila L Stadler
Feb 1, 2013·Therapeutic Advances in Drug Safety·Rachel N LoweJoseph J Saseen
Jul 17, 2014·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Ila M HarrisAhmed M Soliman
Dec 6, 2019·Science Translational Medicine·Ameya R KirtaneGiovanni Traverso
Feb 6, 2020·Dermatologic Therapy·Jennifer M FernandezVivian Y Shi
Aug 28, 2019·Antimicrobial Agents and Chemotherapy·David H SalingerDavid J Hermann
Apr 5, 2014·Imaging Science in Dentistry·Dong-Soo KimEun-Kyung Kim
May 19, 2020·JAMA Neurology·Jeffrey M Gelfand, Jinoos Yazdany
Mar 8, 2016·The Mental Health Clinician·Marketa Marvanova
Jul 15, 2020·Journal of the American Society of Nephrology : JASN·Jung-Im ShinMorgan E Grams
Aug 5, 2020·Expert Opinion on Drug Discovery·Taraneh MousaviMohammad Abdollahi
Jul 7, 2020·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Ramona MontironiJacques C Jani
Jul 28, 2016·Expert Opinion on Drug Safety·H Simon SchaafAnthony J Garcia-Prats
Jul 22, 2017·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Nancy ChenDevin Welty
Jun 14, 2018·Expert Opinion on Drug Metabolism & Toxicology·Tine A BækdalCilie W Hansen
Jan 12, 2019·Expert Opinion on Drug Metabolism & Toxicology·Diego BagnascoGiorgio Walter Canonica
Jul 28, 2019·Drug and Therapeutics Bulletin·Harpreet SinghAlicja Wasilewski
Apr 27, 2017·Expert Review of Anti-infective Therapy·Francisco Antunes
Aug 24, 2016·Expert Opinion on Drug Safety·Terhi HermansonIain C Macdougall
Apr 22, 2019·BMJ Case Reports·Harpreet SinghAlicja Wasilewski
Apr 12, 2014·Drug and Therapeutics Bulletin
Oct 3, 2020·Inflammopharmacology·Alireza HejratiParisa Zafari
Feb 8, 2019·Therapeutic Advances in Drug Safety·Thananan RattanachotphanitOnanong Waleekhachonloet

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.